Contact Us

Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

Chronic kidney disease can be described as the gradual loss of kidney function. In this chronic condition, kidneys can be damaged and cannot filter blood the way they should filter ideally. Chronic kidney disease may be caused by diabetes, high blood pressure, and other disorders. If kidney disease gets worse, metabolic wastes can build to high levels in patient’s blood and make them feel sick. Chronic kidney disease complications include high blood pressure, anemia (low blood count), weak bones, poor nutritional health, and nerve damage. Chronic kidney disease increases the risk of developing heart and blood vessel diseases such as heart attack, stroke etc. These problems may happen slowly over a long period of time.

The global chronic kidney disease drugs market is estimated to be valued at US$ 12,328.2 million in 2020 and is expected to exhibit a CAGR of 4.0% over the forecast period (2020-2027).

Figure 1. Global Chronic Kidney Disease Drugs Market Share (%), By Region, 2020

Chronic Kidney Disease Drugs  | Coherent Market Insights

Increasing prevalence of chronic kidney disease is expected to drive the market growth over the forecast period 

The increasing prevalence of chronic kidney disease is expected to drive growth of the global chronic kidney disease drugs market. For instance, according to the Centers for Disease Control and Prevention (CDC), 15% of adults in the U.S., which is around 37 million people, were estimated to have chronic kidney disease in 2019.

Moreover, according to the data published in the Indian Journal of Public Health (IJPH), in 2018, around 130,000 patients received dialysis treatment in India, and the number increased by around 232 patients per million population in India from previous year

Furthermore, adoption of inorganic growth strategies by major companies operating in this market such as collaborations, agreements, partnerships, and acquisitions to strengthen their market share is further fuelling growth of the global chronic kidney disease drugs market. For instance, in January 2017, Amgen, Inc. entered into a six year sourcing and supply agreement with DaVita Inc., a healthcare company, which offers kidney dialysis services. Under this agreement, Amgen will supply Epogen and Aransep, major anemia drugs, to DaVita Inc.

Figure 2. Global Chronic Kidney Disease Drugs Market Share (%), by Drug Type, 2020

Chronic Kidney Disease Drugs  | Coherent Market Insights

Increasing launches and approval of products are expected to drive the market growth over the forecast period

Key players operating in the market are focusing on novel product launches and approvals, in order to expand their product portfolio and strengthen their presence in the global market.

For instance, in August 2017, Amgen, Inc. received approval from the European Commission (EC) for expanded use of Mimpara (cinacalcet) for the treatment of secondary hyperparathyroidism (HPT) in children aged three years and older with end?stage renal disease (ESRD) on dialysis and where secondary HPT is not adequately controlled with standard of care therapy.

Furthermore, in February 2017, Amgen, Inc. received approval from the U.S. Food and Drug Administration (FDA) for its Parsabiv (etelcalcetide) indicated for the treatment of secondary hyperparathyroidism (sHPT) in adult patients with chronic kidney disease (CKD) on hemodialysis.

request-sample

Chronic Kidney Disease Drugs Market Report Coverage

Report Coverage Details
Base Year: 2019 Market Size in 2020: US$ 12,328.2 Mn
Historical Data for: 2016 to 2019 Forecast Period: 2020 to 2027
Forecast Period 2020 to 2027 CAGR: 4.0% 2027 Value Projection: US$ 16,222.7 Mn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC Countries, Israel, and Rest of Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Drug Type: ACE Inhibitors, B-blockers, Calcium Channel Blockers, Loop Diuretics, Erythropoiesis-stimulating Agents (ESAs), Phosphate Binders, Others.
  • By Route of Administration: Oral, Intravenous, Subcutaneous.
  • By Patient Type: Dialysis, Others.
  • By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies.
Companies covered:

Amgen, Inc., Pfizer Inc., Teva Pharmaceutical Industries Ltd., AstraZeneca Plc, Hoffmann La Roche Ltd., Sanofi S.A., Kissei Pharmaceutical Co. Ltd., AbbVie Inc., Reata Pharmaceuticals, Inc., GlaxoSmithKline Plc, and Ardelyx, Inc.

Growth Drivers:
  • Increasing prevalence of chronic kidney disease
  • Product approvals and launches for the treatment of chronic kidney disease
  • Adoption of inorganic growth strategies by market players
Restraints & Challenges:
  • Lack of awareness about chronic kidney disease

Global Chronic Kidney Disease Drugs Market – Impact of Coronavirus (Covid-19) Pandemic

Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization declared it as a public health emergency. According to the Coronavirus Disease (COVID-19) Weekly Epidemiological Update by the World Health Organization, over 49.7 million cases and 1.2 million deaths due to coronavirus disease (COVID-19) were reported up till November 08, 2020, across the globe. With dynamically surging cases of COVID-19, the risk for patients acquiring chronic kidney disease is also increasing. According to a study conducted in May 2020, by the researchers at Mount Sinai Health System, New York City, U.S., an epidemic of post-COVID-19 kidney disease might occur after the COVID-19. Moreover, according to the National Kidney Foundation, a study found that patients hospitalized during March 11 and April 26, 2020, due to COVID-19 were twice as likely to develop acute kidney injury (AKI) as compared to non-COVID patients, who developed AKI during the same time period in 2019.

The COVID-19 pandemic has drastically affected clinical trials. Many trials have paused enrollment and researchers are facing multiple challenges associated with setting up remote visits, and performing laboratory and other study assessments. According to a survey conducted by Medidata Solutions, Inc. (a U.S.-based technology company, which develops and markets software as a service for clinical trials), on April 23, 2020, 63% of survey respondents reported that they stopped recruiting new patients for ongoing clinical trials and 43% of the respondents have postponed their studies. However, market players and research institutes are focusing on initiating clinical trials associated with COVID-19, in order to understand the effects of chronic kidney disease treatment drugs on patients suffering with COVID-19.

Global Chronic Kidney Disease Drugs Market - Restraint

Lack of awareness about chronic kidney disease is the major factor that is expected to restrain growth of the chronic kidney disease drugs market. Despite the attempts by government to increase awareness about chronic kidney disease (CKD) through dissemination of clinical practice guidelines and recommendations for patients with CKD or its risk factors, community awareness events such as World Kidney Day, and free screening efforts for high-risk individuals such as Kidney Early Evaluation Program (KEEP), the awareness of CKD remains unacceptably low. For instance, in March 2018, a cross-sectional study for chronic kidney disease evaluation was published in BMC Public Health, according to which the people in Australia have very poor understanding of chronic kidney disease (CKD) and only half of the participants knew that medications can help to slow the worsening of CKD.  Furthermore, only 23.4% of participants of total chronic kidney disease knew that herbal supplements are ineffective in treating CKD.

Key Players

Major players operating in the global chronic kidney disease drugs market include Amgen, Inc., Teva Pharmaceutical Industries Ltd., Pfizer Inc., AstraZeneca Plc, Hoffmann La Roche Ltd., Sanofi S.A., Kissei Pharmaceutical Co. Ltd., AbbVie Inc., Reata Pharmaceuticals, Inc., GlaxoSmithKline Plc, and Ardelyx, Inc.

Chronic kidney disease is the lasting damage to the kidneys that can get worse over time. If the damage is very bad, kidneys may stop working. This is called kidney failure, or end-stage renal disease (ESRD). In this condition, kidneys are damaged and cannot filter blood in the usual way. If kidney disease gets worse, wastes can build to high levels in patient’s blood and make the patient feel sick. Chronic kidney disease may be caused by diabetes, high blood pressure and other disorders. Damage to kidneys is usually permanent. Although the damage cannot be fixed, symptoms such as muscle twitches, cramps, fatigue, heart problems, swelling of feet and ankles can be managed to control by certain medications such as ACE inhibitors and calcium channel blockers.

Market Dynamics

Rising prevalence of chronic kidney disease, increasing launches & approval of new products for the treatment of chronic kidney disease, and increasing adoption of inorganic growth strategies such as collaboration and acquisition by key players operating in the market are expected to drive the growth of global chronic kidney disease drugs market over the forecast period. For instance, In August 2019, GSK submitted a Japanese New Drug Application (JNDA) to the Ministry of Health, Labor and Welfare seeking approval for Duvroq (daprodustat) tablets, indicated for the treatment of anemia associated due to chronic kidney disease (CKD). Later, on 29 June 2020, GSK received approval for Duvroq (daprodustat) from the Ministry of Health, Labor and Welfare, Japan.

Key features of the study:

  • This report provides in-depth analysis of the global chronic kidney disease drugs market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2020–2027), considering 2019 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends,  regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global chronic kidney disease drugs market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
  • Key companies covered as a part of this study include Amgen, Inc., Teva Pharmaceutical Industries Ltd., Pfizer Inc., AstraZeneca Plc, Hoffmann La Roche Ltd., Sanofi S.A., Kissei Pharmaceutical Co. Ltd., AbbVie Inc., Reata Pharmaceuticals, Inc., GlaxoSmithKline Plc, and Ardelyx, Inc.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global chronic kidney disease drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global chronic kidney disease drugs market

Detailed Segmentation:

  • Global Chronic Kidney Disease Drugs Market, By Drug Type:
    • ACE Inhibitors
    • B-blockers
    • Calcium Channel Blockers
    • Loop Diuretics
    • Erythropoiesis-stimulating Agents (ESAs)
    • Phosphate Binder
    • Others
  • Global Chronic kidney Disease Drugs Market, By Route of Administration:
    • Oral
    • Intravenous
    • Subcutaneous
  • Global Chronic kidney Disease Drugs Market, By Patient Type:
    • Dialysis
    • Others
  • Global Chronic Kidney Disease Drugs Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Chronic Kidney Disease Drugs Market, By Region:
    • North America
      • By Drug Type:
        • ACE Inhibitors
        • B-Blockers
        • Calcium Channel Blockers
        • Loop Diuretics
        • Erythropoiesis-Stimulating Agents (ESAs)
        • Phosphate Binders
        • Others
      • By Route of Administration:
        • Oral
        • Intravenous
        • Subcutaneous
      • By Patient Type:
        • Dialysis
        • Others
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • U.S.
        • Canada
    • Latin America
      • By Drug Type:
        • ACE Inhibitors
        • B-Blockers
        • Calcium Channel Blockers
        • Loop Diuretics
        • Erythropoiesis-Stimulating Agents (ESAs)
        • Phosphate Binders
        • Others
      • By Route of Administration:
        • Oral
        • Intravenous
        • Subcutaneous
      • By Patient Type:
        • Dialysis
        • Others
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Drug Type:
        • ACE Inhibitors
        • B-Blockers
        • Calcium Channel Blockers
        • Loop Diuretics
        • Erythropoiesis-Stimulating Agents (ESAs)
        • Phosphate Binders
        • Others
      • By Route of Administration:
        • Oral
        • Intravenous
        • Subcutaneous
      • By Patient Type:
        • Dialysis
        • Others
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Drug Type:
        • ACE Inhibitors
        • B-Blockers
        • Calcium Channel Blockers
        • Loop Diuretics
        • Erythropoiesis-Stimulating Agents (ESAs)
        • Phosphate Binders
        • Others
      • By Route of Administration:
        • Oral
        • Intravenous
        • Subcutaneous
      • By Patient Type:
        • Dialysis
        • Others
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Drug Type:
        • ACE Inhibitors
        • B-Blockers
        • Calcium Channel Blockers
        • Loop Diuretics
        • Erythropoiesis-Stimulating Agents (ESAs)
        • Phosphate Binders
        • Others
      • By Route of Administration:
        • Oral
        • Intravenous
        • Subcutaneous
      • By Patient Type:
        • Dialysis
        • Others
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Drug Type:
        • ACE Inhibitors
        • B-Blockers
        • Calcium Channel Blockers
        • Loop Diuretics
        • Erythropoiesis-Stimulating Agents (ESAs)
        • Phosphate Binders
        • Others
      • By Route of Administration:
        • Oral
        • Intravenous
        • Subcutaneous
      • By Patient Type:
        • Dialysis
        • Others
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country/Region:
        • South Africa
        • Central Africa
        • North Africa
  • Company Profiles
    • Amgen, Inc. *
      • Company Overview
      • Material Portfolio
      • Financial Performance
      • Key Highlights
      • Market Strategies
    • Teva Pharmaceutical Industries Ltd.
    • Pfizer, Inc.
    • AstraZeneca Plc
    • Hoffmann La Roche Ltd.
    • Sanofi S.A.
    • Kissei Pharmaceutical Co. Ltd.
    • AbbVie Inc.
    • Reata Pharmaceuticals, Inc.
    • GlaxoSmithKline Plc
    • Ardelyx, Inc.

 “*” marked represents similar segmentation in other categories in the respective section

Table of Contents

  1. Research Objectives and Assumptions
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Drug Type
      • Market Snippet, By Route of Administration
      • Market Snippet, By Patient Type
      • Market Snippet, By Distribution Channel
      • Market Snippet, By Region
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • CKD Stages Treatment Options
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Impact Analysis
    • Market Trends
    • Product Launch/Approvals
    • Collaboration & Agreements
    • Pipeline Analysis
    • Regulatory Scenario
    • Reimbursement Scenario
    • PEST Analysis
    • Epidemiology
    • Adherence Rate in the U.S.
  4. Global Chronic Kidney Disease Drugs Market – Impact of Coronavirus (Covid-19) Pandemic
    • Acute Kidney Injury Due to COVID-19
    • Impact of COVID-19 on Clinical Trials and Drug Development
  5. Global Chronic Kidney Disease Drugs Market, By Drug Type, 2016 – 2027, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • ACE Inhibitors
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • B-blockers
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Calcium Channel Blockers
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Loop Diuretics
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Erythropoiesis-stimulating Agents (ESAs)
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Phosphate Binders
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Others
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
  6. Global Chronic Kidney Disease Drugs Market, By Route of Administration, 2016 – 2027, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Oral
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Intravenous
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Subcutaneous
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
  7. Global Chronic Kidney Disease Drugs Market, By Patient Type, 2016 – 2027, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Dialysis
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Others
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
      •  
  8. Global Chronic Kidney Disease Drugs Market, By Distribution Channel, 2016 – 2027, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Hospital Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Online Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Retail Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
  9. Global Chronic Kidney Disease Drugs Market, By Region, 2016 – 2027, (US$ Mn)
    • Introduction
      • Market Share Analysis, By Region, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, For Regions, 2017–2027
    • North America
      • Market Size and Forecast, By Drug Type, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Route of Administration, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Patient Type, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • U.S.
        • Canada
    • Latin America
      • Market Size and Forecast, By Drug Type, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Route of Administration, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Patient Type, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • Market Size and Forecast, By Drug Type, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Route of Administration, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Patient Type, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast, By Drug Type, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Route of Administration, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • Market Size and Forecast, By Drug Type, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Route of Administration, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Patient Type, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • Market Size and Forecast, By Drug Type, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Route of Administration, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Patient Type, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country/Region, 2016 – 2027, (US$ Mn)
        • South Africa
        • Central Africa
        • North Africa
  10. Competitive Landscape
    • Heat Map Analysis
    • Company Profiles
      • Amgen, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Teva Pharmaceutical Industries Ltd.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Pfizer, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • AstraZeneca Plc
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Hoffmann La Roche Ltd.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Sanofi S.A.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Kissei Pharmaceutical Co. Ltd.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • AbbVie Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Reata Pharmaceuticals, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • GlaxoSmithKline Plc
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Ardelyx, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
  11. Section
    • References
    • Research Methodology
    • About us and Sales Contact

*Browse 44 market data tables and 39 figures on "Chronic Kidney Disease Drugs Market” - Global Forecast to 2027

Frequently Asked Questions

The global chronic kidney disease drugs market is estimated to be valued at US$ 12,328.2 million in 2020 and is expected to exhibit a CAGR of 4.0% between 2020 and 2027.
The increasing prevalence of chronic kidney disease across the globe, increasing launch & approval of products for CKD treatment, and adoption of inorganic growth strategies such as merger, acquisition, & collaboration by market players are expected to drive the market growth over the forecast period.
Erythropoiesis-stimulating Agents (ESAs) is the leading drug type segment in the chronic kidney disease drugs market.
North America is expected to hold the largest market share in the global chronic kidney disease drugs market.
Lack of awareness about chronic kidney disease is the major factor that is expected to restrain growth of the chronic kidney disease drugs market.
Major players operating in the global chronic kidney disease drugs market include Amgen, Inc., Teva Pharmaceutical Industries Ltd., Pfizer Inc., AstraZeneca Plc, Hoffmann La Roche Ltd., Sanofi S.A., Kissei Pharmaceutical Co. Ltd., AbbVie Inc., Reata Pharmaceuticals, Inc., GlaxoSmithKline Plc, and Ardelyx, Inc.
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner